Getinge AB B

Getinge is engaged in three business areas: Medical Systems, Extended Care and Infection Control. Medical System's product range includes surgical tables, surgical lamps, telemedicine, perfusion products, instruments for bypass operations, ventilators, anesthesia systems, synthetic vascular implants and stents. Extended Care's product range includes bathing and shower solutions, lifting equipment and mattresses for the treatment and prevention of pressure ulcers, as well as service and consulting. Infection Control's product range comprises disinfectors, sterilizers, information technology systems and related equipment, as well as service and consulting.
  • TickerGETI B
  • ISINSE0000202624
  • ExchangeNasdaq Nordic Stockholm
  • SectorHealth Care Equipment & Services
  • CountrySweden

Analysts

Mattias Holmberg ...
  • Nicolas McBeath
  • Ole-Andreas Krohn
  • Olof Larshammar
  • Patrik Ling
  • Rune Majlund Dahl

Northern Lights

Aksel Øverland Engebakken ...
  • Daniel Thorsson
  • Erik Moberg
  • Fredrik Ivarsson
  • Peter Kurt Nielsen
  • Victor Forssell

Talking Points - Kesko (Sell): Unappetising shopping trends

MTG (Buy) Preview: Long-term case intact Downside risk to grocery margins Initiating coverage with SELL

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Getinge - Stakes have been raised

Q4 report on 30 January at 8.00 CET Q4e: org. sales +3.2%, adj. EBITA growth of 11% Valuation already capturing further margin improvements

Patrik Ling

Getinge (Buy, TP: SEK200.00) - Solid end to 2019e

We expect Q4 to be another healthy quarter (results due at 08:00 CET on 30 January). After strong performance in Q3, we fear some revenues were brought forward from Q4 but we still believe the company will reach the upper end of its 2019 guidance of 2–4% growth. We reiterate our BUY and have raised our target price to SEK200 (180) on higher long-term forecasts.

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Getinge - Additional settlements with Brazilian authority

Settlements in Brazil leading to fines of SEK 35m Not much left of the SEK 350m provision Estimates remain intact, but share sentiment may suffer

Aksel Øverland Engebakken ...
  • Daniel Thorsson
  • Erik Moberg
  • Fredrik Ivarsson
  • Peter Kurt Nielsen
  • Victor Forssell

Talking Points - Kesko (Sell): Unappetising shopping trends

MTG (Buy) Preview: Long-term case intact Downside risk to grocery margins Initiating coverage with SELL

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Getinge - Stakes have been raised

Q4 report on 30 January at 8.00 CET Q4e: org. sales +3.2%, adj. EBITA growth of 11% Valuation already capturing further margin improvements

Patrik Ling

Getinge (Buy, TP: SEK200.00) - Solid end to 2019e

We expect Q4 to be another healthy quarter (results due at 08:00 CET on 30 January). After strong performance in Q3, we fear some revenues were brought forward from Q4 but we still believe the company will reach the upper end of its 2019 guidance of 2–4% growth. We reiterate our BUY and have raised our target price to SEK200 (180) on higher long-term forecasts.

Rickard Anderkrans ...
  • Victor Forssell
  • Viktor Sundberg

Getinge - Additional settlements with Brazilian authority

Settlements in Brazil leading to fines of SEK 35m Not much left of the SEK 350m provision Estimates remain intact, but share sentiment may suffer

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior